<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-112768</identifier>
<setSpec>1130-0108</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Vaccination of patients with inflammatory bowel disease. Practical recommendations</dc:title>
<dc:description xml:lang="en">Patients with inflammatory bowel disease (IBD) have a greater risk of infection associated with the endogenous immunosuppression brought about by their underlying disease as well as the exogenous immunosuppression resulting from their therapies. In the last few years guidelines and consensus papers have been issued on the indication of vaccines for these patients as primary prevention of infection. However, vaccine coverage is low, likely because the risk for infection and both safety and efficacy concerns regarding vaccines are scarcely perceived in such cases. The available scientific evidence shows that immunization is safe for most preparations, and bears no association with an increased risk for disease activity. This paper reviews the available scientific literature, and provides recommendations on the vaccination of adults with IBD(AU)</dc:description>
<dc:creator>Martínez, Xavier</dc:creator>
<dc:creator>Campins, Magda</dc:creator>
<dc:creator>Cossio, Yolima</dc:creator>
<dc:creator>Borruel, Natalia</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Los pacientes con enfermedad inflamatoria intestinal (EII) tienen un mayor riesgo de infecciones, asociado tanto a la inmunosupresión endógena condicionada por su enfermedad de base, como a la exógena generada por los tratamientos que reciben. En los últimos años se han publicado guías y documentos de consenso sobre indicaciones de vacunación en estos pacientes, como medida de prevención primaria de infecciones. Sin embargo, las coberturas vacunales alcanzadas son bajas, probablemente por la falta de percepción del riesgo de infección y las dudas sobre la seguridad y eficacia de las vacunas en estos casos. La evidencia científica disponible muestra que la inmunización es segura para la mayoría de preparados y no se asocia a un incremento del riesgo de actividad de la enfermedad. En este documento se revisa la literatura científica disponible y se presentan unas recomendaciones de vacunación para pacientes adultos con EII(AU)</dc:description>
<dc:source>Rev Esp Enferm Dig;105(2): 93-102, feb. 2013. tab</dc:source>
<dc:identifier>ibc-112768</dc:identifier>
<dc:title xml:lang="es">Vacunación de pacientes con enfermedad inflamatoria intestinal. Recomendaciones prácticas</dc:title>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d6721^s22038</dc:subject>
<dc:subject>^d23695^s22038</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d29482^s22074</dc:subject>
<dc:subject>^d29592^s22074</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d29431^s22074</dc:subject>
<dc:subject>^d2689^s22038</dc:subject>
<dc:subject>^d6664^s22038</dc:subject>
<dc:subject>^d22622^s22073</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d29482^s22045</dc:subject>
<dc:subject>^d29315</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d23109^s22038</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d23695^s22080</dc:subject>
<dc:subject>^d11758^s22048</dc:subject>
<dc:subject>^d10399^s22038</dc:subject>
<dc:subject>^d11758^s22049</dc:subject>
<dc:subject>^d29431^s22045</dc:subject>
<dc:subject>^d1394^s22073</dc:subject>
<dc:subject>^d53386</dc:subject>
<dc:subject>^d29592^s22045</dc:subject>
<dc:type>article</dc:type>
<dc:date>201302</dc:date>
</metadata>
</record>
</ibecs-document>
